[en] Familial acromegaly is an exceptional clinical entity when not associated with features of multiple endocrine neoplasia type 1 (MEN1). We report here 3 pedigrees in each of which 2 patients have been shown to develop acromegaly. In 4 patients, clinical follow-up, and biological screening allowed to confidently exclude MEN1. Absence of mutation in the MEN1 gene after direct DNA analysis in 2 pedigrees reinforces the conviction that the families do not have MEN1. In families 1 and 2, diagnosis was made at a very early age and voluminous adenomas with suprasellar expansion were already present at the time of diagnosis. We review the 20 previous reports of familial acromegaly, some of them questionable. Our 3 families, combined with some other published pedigrees, allow the delineation of a familial form of acromegaly, distinct from MEN1. Dominant inheritance with reduced, age-dependant penetrance is the most parsimonious model to explain the recurrences. Gs protein pathway could be the site of action of the gene responsible of familial acromegaly, but no data have been published to sustain or reject this hypothesis.
Koch G, Tiwisina T. Contribution to the hereditary of acromegaly and hyperostosis generalisata with pachyderma (chromophobe hypophysis adenoma in father and son). Arznemittel Furschung 1959;13:489-504.
Stevenaert A, Beckers A. Presurgical octreotide: treatment in acromegaly. Metab Clin Exp 1996;45(suppl. 1):72-74.
Teh BT, Kytölä S, Farnebo L, Bergman FK, Wong K, et al. Mutation analysis of the MEN1 gene in multiple endocrine neoplasia type I, familial acromegaly and familial isolated hyperparathyroidism. J Clin Endocrinol Metab 1998;83: 2621-2628.
Poncin J, Abs B, Velkeniers M, Bonduelle M, Abramovicz M, et al. Mutation analysis of the MEN1 gene in Belgian patients with multiple endocrine neoplasia type 1 and related diseases. Human Mutation 1998;(in press)
Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf) 1980;12:71-79.
Bengtsson BA, Eden S, Ernest I, Oden A, Sjoegren B. Epidemiology and long-term survival in acromegaly. Acta Medica Scand 1988;223:327-335.
Beckers A, Courtoy R, Stevenaert A, Bonniver J, Closset J, et al. Mammosomatotropes in human pituitary adenomas as revealed by electron microscopic double gold immunostaining method. Acta Endocrinol (Copenh) 1988;118:503-512.
Herman V, Fagin J, Govsky R, Kovacs K, Melmed S. Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 1990; 71:1427-1433.
Vallar L, Spada A, Giancannattasio G. Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 1987;330:566-568.
Hosoi E, Yokogoshi Y, Horie H, Yamada S, Saito S. Analysis of the GS alpha gene in growth hormone-secreting pituitary adenomas by the polymerase chain reaction-direct sequencing method using paraffin-embedded tissues. Acta Endocrinol (Copenh) 1993;129:301-306.
Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, et al. GTPase inhibiting mutations activate the alpha chain of of Gs and stimulate adenylate cyclase in human pituitary tumors. Nature 1989;340:692-696.
Faglia G, Arosio M, Spada A. GS protein mutations and pituitary tumors: Functional correlates and possible therapeutic implications. Metabolism 1996;45 (suppl.1):117-119.
Lania A, Persani L, Ballare E, Mantovani S, Losa M, et al. Constitutively active Gs alpha is associated with an increased phosphodiesterase activity in human growth hormone-secreting adenomas. J Clin Endocrinol Metab 1998; 85:1624-1628.
Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, et al. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. New Engl J Med 1991;325:1738-1740.
Croizier JC, Azerad E, Lubetski J. L'adénomatose polyendocrinienne (syndrome de Wermer): a propos d'une observation personnelle. Revue de la littérature. Sem Hôp Paris 1971;47:494-525.
Eberle F, Grün R. Multiple endocrine neoplasia, type 1. Ergebn Inn Med Kinderheilk (Berlin) 1981;46:75-142.
Benson L, Ljunghall S, Akerström G, Öberg K. Hyperparathyroidism presenting as the first lesion in multiple endocrine neoplasia type 1. Am J Med 1987;82:731-737.
Samaan NA, Ouais S, Ordonez NG, Choksi UA, Sellin RV, et al. Multiple endocrine syndrome type 1. Clinical, laboratory findings and management in five families. Cancer 1989;84: 741-752.
Tateishi A, Wada A, Ishiguro S, Ehara M, Sakamoto H, et al. Coexistence of bilateral pheochromocytoma and pancreatic islet cell tumor: report of a case and review of the literature. Cancer 1978;42:2928-2934.
Lemmens I, Van de Ven WJ, Kas K, Zhang CX, Giraud S, et al. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Hum Mol Genet 1997;6:1177-1183.
Agarwal SK, Kester MB, Debelenko LV, Heppner C, Emmert-Buck MR, et al. Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet 1997;6:1169-1175.
Bassett JH, Forbes SA, Pannett AA, Lloyd SE, Christie PT, et al. Characterization of mutations in patients with multiple endocrine neoplasia type 1. Am J Hum Genet 1998;62:232-244.
Giraud S, Zhang CX, Serova-Sinilnikova O, Wautot V, Salandre J, et al. Germ-Line Mutation Analysis in Patients with Multiple Endocrine Neoplasia Type 1 and Related Disorders. Am J Hum Genet 1998;63:455-467.
Hosoi E, Yokogoshi Y, Yokoi K, Sano T, Saito S. A pituitary-specific point mutation of codon 201 of the GSalpha genein a pituitary adenoma of a patient with multiple endocrine neoplasia (MEN) type 1. Endocrinol Jpn 1992;39:319-324.
O'Halloran DJ, Shalet SM. A family pedigree exhibiting features of both multiple endocrine neoplasia type 1 and McCune-Albright syndromes. J Clin Endocrinol Metab 1994;78:523-525.
Carney JA, Gordon H, Carpenter PCSBV, Go VLW. The complex of myxomas, spotty pigmentation and endocrine overactivity. Medicine 1985;64:270-283.
Levin SR, Hofeldt PD, Becker N, Wilson CB, Seymour R, et al. Hypersomatotropism and acanthosis nigricans in 2 brothers. Arch Intern Med 1974;1974:355-357.
Jones MK, Evans PJ, Jones IR, Thomas TS. Familial acromegaly. Clin Endocrinol (Oxf) 1984;20:355-358.
Himuro H, Kobayashi EKH, Jimbo M, Kitazawa M. Pituitary adenomas in two members of a family. Neurol Surg 1976;4:371-377.
Kurisaka M, Takei Y, Tsubokawa T, Moriyasu N. Growth hormone-secreting pituitary adenoma in uniovular twin brothers. Case report. Neurosurgery 1981;8:226-230.
Abbassioun K, Fatourehchi V, Amirjamshidi A, Meibodi NA. Familial acromegaly with pituitary adenoma: report of 3 affected siblings. J Neurosurg 1986;64:510-512.
Yuasa H, Tokito S, Nakagaki H, Kitazawa M. Familial pituitary adenoma, report of four cases from two unrelated families (in Japanese, with English abstract). Neurol Med Chir (Tokyo) 1990;30:1016-1019.
Tamburrano G, Jaffrain-Rea ML, Grossi A, Lise A, Bulletta C. L'acromégalie familiale: a propos d'une observation. Revue de la litterature. Ann Endocrinol (Paris) 1992;53:201-207.
Links TP, Monkelban JF, Dullaart RPF, van Haeften TW Growth hormone-, alpha-subunit and thyrotrophin-cosecreting pituitary adenoma in familial setting of pituitary tumor. Acta Endocrinol (Copenh) 1993;129:516-518.
Matsuno A, Teramoto A, Yamada S, Kitanaka T, et al. Gigantism in siblings unrelated to multiple endocrine neoplasia: case report. Neurosurgery 1994;35:952-955.
Benlian P, Giraud S, Lahlou N, Roger M, Blin C, et al. Familial acromegaly: A specific clinical entity - Further evidence from the genetic study of a three-generation family. Eur J Endocrinol 1995;133:451-456.
Stock JL, Warth MR, Teh BT, Coderre JA, Overdorf JH, et al. A kindred with a variant of multiple endocrine neoplasia type 1 demonstrating frequent expression of pituitary tumors but not linked to the multiple endocrine neoplasia type 1 locus at chromosome region 11q13. J Clin Endocrinol Metab 1997;82:486-492.
Chedid A, Hoversi, Chefiec, McCune SA, Jurin RR, et al. Hereditary pituitary proclamation: A new rat mode. Acta Endocrinol (Copenh) 1988;119:535-542.
